View Post

Patient-Reported Outcomes Predictive of PFS in Patients Receiving Abemaciclib for Advanced Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Jennifer Larson From: cancertherapyadvisor.com Pretreatment patient-reported outcomes (PROs) are potential prognostic tools for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) advanced breast cancer who are undergoing treatment with abemaciclib, a CDK4/6 inhibitor, according to a team of researchers based in Australia. Their findings were published in The Oncologist. The researchers developed a model based on data …

View Post

Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients

In Clinical Studies News by Barbara Jacoby

Source: Novartis Pharmaceuticals Corporation From: prnewswire.com MONALEESA-3 median overall survival (OS) results of 53.7 months underscore that Kisqali offers more life to postmenopausal women with HR+/HER2- metastatic breast cancer (MBC) in addition to the OS benefit demonstrated for premenopausal women as shown in MONALEESA-7(1,2) The relative risk reduction of death by 36% in the MONALEESA-3 first-line (1L) postmenopausal population highlights …

View Post

First patient treated with Clarity’s copper-64 SAR-Bombesin in breast cancer clinical trial

In Clinical Studies News by Barbara Jacoby

From: dotmed.com Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that the first patient has been treated in the C-BOBCAT study (Copper-64 BOmbesin in Breast CAncer Trial). The C-BOBCAT trial is a first-in-human, investigator-led clinical trial investigating 64Cu-SAR-Bombesin (SAR-BBN) in patients with hormone receptor positive/HER2 negative (HR+/HER2-) metastatic breast cancer. The trial …

View Post

Dosing underway in Oncolytics Bio combo study in breast cancer

In Clinical Studies News by Barbara Jacoby

By: Mamta Mayani, SA News Editor From: seekingalpha.com Oncolytics Biotech (NASDAQ:ONCY) doses first patient in its phase 2 study of pelareorep-based combination therapies in HR+/HER2- metastatic breast cancer (mBC). The study, known as BRACELET-1, is being conducted under a co-development agreement with Merck KGaA (OTCPK:MKGAY) and Pfizer (NYSE:PFE). Participants will receive paclitaxel, pelareorep in combination with paclitaxel alone, or pelareorep in combination with …